Sold out
LOAD MORE
You're viewed all 11 products
Azilsartan
References
FAQ's
References
- Naka, Takehiko; Inada, Yoshiyuki, Compound which is angiotensin II antagonist, Takeda Chemical Industries, Ltd., Japan, US5243054A, September 7, 1993
- Mantena, Bhaskara P. V.; Rao, Sumathi V.; Appa Rao, K. M. Ch.; Ramakrishna, K.; Srikanth Reddy, R., Method Development and Validation for the Determination of Potential Impurities Present in Azilsartan medoxomil Tablets by Reverse Phase-Ultra Performance Liquid Chromatography, Analytical Chemistry Letters, Volume: 4, Issue: 5-6, Pages: 287-301, 2014
Frequently Asked Questions
What are the genotoxic impurities in Azilsartan?
Genotoxic impurities are substances that can damage DNA and potentially cause cancer. They are typically present in low levels of drug substances.
How can Azilsartan impurities be minimized during the manufacturing of the drug?
Impurities in Azilsartan can be minimized during manufacturing by using high-quality starting materials, optimizing reaction conditions, and implementing appropriate purification steps.
Can impurities in Azilsartan vary between different batches?
Impurities in Azilsartan can vary between batches due to factors such as the quality of starting materials, manufacturing process, and storage conditions.
What are the temperature conditions required to store Azilsartan impurities?
Azilsartan impurities are stored at recommended temperature conditions, typically 2-8°C or -20°C depending on their stability.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.